Back to Dashboard
EZH-302
Lymphoma
•
NCT04224493
•
Last updated: 2/17/2026
Recruiting
Study Design
Study Drug
Tazemetostat+ R2
Mechanism of Action
EZH 2 innibitor
Sponsor
Unknown
Design
III
Control Arm
placebo +R2
Criteria
Inclusion Criteria
≥1 prior Tx
Age: Phase: III
Exclusion Criteria
Enrollment
Progress
6 / 6
Contact Information
Principal Investigator
Unknown
Study Nurse
鄭采涵
Contact Tel
3974